Tonix Pharmaceuticals Holding develops innovative prescription medications for disorders of the central nervous system. The company targets conditions with significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among patients and physicians. TNXP’s core technology improves the quality of sleep in patients with chronic pain syndromes. TNXP’s lead product candidate, TNX-102 SL, is expected to enter a phase 3 program in early 2013. For more information, visit the company’s Web site at www.tonixpharma.com.
LD Micro is an internet-based newsletter that provides information on selected public companies to self-directed investors. It is anticipated that the two-day LD Micro Conference will be attended by more than 200 institutions focused on micro-cap and small-cap stocks. Last year, a record 580 people attended. For more information, please visit www.ldmicro.com.
Let us hear your thoughts below:
